Effect of clopidogrel on tissue-plasminogen activator-induced in vitro thrombolysis of feline whole blood thrombi

American Journal of Veterinary Research

Volumn 65, Issue 6, 2004, Pages 715-719

  Hogan, Daniel F ^a   Ward, Michael P ^a  

^a PURDUE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CALCIUM CHLORIDE; CITRATE SODIUM; CLOPIDOGREL; FIBRIN DEGRADATION PRODUCT; FIBRINOGEN; FIBRINOGEN RECEPTOR; HEPARIN; IODINE 125; SEROTONIN; TISSUE PLASMINOGEN ACTIVATOR; WARFARIN;

ANIMAL EXPERIMENT; ANTICOAGULATION; ARTICLE; BLOOD CLOT LYSIS; BLOOD SAMPLING; CAT DISEASE; CONTROLLED STUDY; DISSOLUTION; FEMALE; IN VITRO STUDY; MALE; NONHUMAN; THROMBOGENESIS; THROMBUS;

ANIMALS; CAT DISEASES; CATS; FIBRINOLYTIC AGENTS; PLATELET AGGREGATION INHIBITORS; THROMBOEMBOLISM; TICLOPIDINE; TIME FACTORS; TISSUE PLASMINOGEN ACTIVATOR;

ANIMALIA; BOVINAE; FELIDAE; FELIS CATUS;

EID: 3042671809     PISSN: 00029645     EISSN: None     Source Type: Journal    
DOI: 10.2460/ajvr.2004.65.715     Document Type: Article

References (58)

1. Harpster NK. Feline myocardial diseases. In: Kirk RW, ed. Current veterinary therapy IX. Philadelphia: WB Saunders Co, 1986; 380-388.
2. Bonagura JD, Fox PR. Restrictive cardiomyopathy. In: Bonagura JD, ed. Kirk's current veterinary therapy XII. Philadelphia: WB Saunders Co, 1995;863-867.
3. Smith SA, Tobias AH, Jacob KA, et al. Arterial thromboembolism in cats: acute crisis in 127 cases (1992-2001) and long-term management with low-dose aspirin in 24 cases. J Vet Intern Med 2003;17:73-83.
4. Laste NJ, Harpster NK. A retrospective study of 100 cases of feline distal aortic thromboembolism: 1977-1993. J Am Anim Hosp Assoc 1995;31:492-500.
5. Fox PR. Myocardial diseases. In: Ettinger SJ, ed. Textbook of veterinary internal medicine. 3rd ed. Philadelphia: WB Saunders Co, 1995; 248-287.
6. Pion PD. Cardiomyopathy in the cat and its relation to taurine deficiency. In: Kirk RW, ed. Current veterinary therapy X. Philadelphia: WB Saunders Co, 1989;251-262.
7. Pion PD. Feline aortic thromboemboli and the potential utility of thrombolytic therapy with tissue plasminogen activator. Vet Clin North Am Small Anim Pract 1988;18:79-86.
8. Felberg RA, Naidech AM. The 5 Ps of acute ischemic stroke treatment: parenchyma, pipes, perfusion, penumbra, and prevention of complications. South Med J 2003;96:336-342.
9. Zweifler RM. Management of acute stroke. South Med J 2003; 96:380-385.
10. Franzosi MG, Santoro E, De Vita C, et al. Ten-year follow-up of the first megatrial testing thrombolytic therapy in patients with acute myocardial infarction: results of the Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto-1 study. The GISSI Investigators. Circulation 1998;98:2659-2665.
11. Califf RM. Ten years of benefit from a one-hour intervention. Circulation 1998;98:2649-2651.
12. Pion PD. Therapy for feline aortic thromboembolism. In: Kirk RW, ed. Current veterinary therapy X. Philadelphia: WB Saunders Co, 1989;295-302.
13. Helenski CA, Ross JN. Platelet aggregation in feline cardiomyopathy. J Vet Intern Med 1987;1:24-28.
14. Welles EG, Boudreaux MK, Crager CS, et al. Platelet function and antithrombin, plasminogen, and fibrinolytic activities in cats with heart disease. Am J Vet Res 1994;55:619-627.
15. Schaub RG, Meyers KM, Sande RD, et al. Inhibition of feline collateral vessel development following experimental thrombotic occlusion. Circ Res 1976;39:736-743.
16. Butler HC. An investigation into the relationship of an aortic emboli to posterior paralysis in the cat. J Small Anim Pract 1971; 12:141-158.
17. Olmstead ML, Butler HC. Five-hydroxytryptamine antagonists and feline aortic embolism. J Small Anim Pract 1977;18:247-259.
18. Allen DG, Johnstone IB, Crane S. Effects of aspirin and propranolol alone and in combination on hemostatic determinants in the healthy cat. Am J Vet Res 1985;46:660-663.
19. Greene CE. Effects of aspirin and propranolol on feline platelet aggregation. Am J Vet Res 1985;46:1820-1823.
20. Behrend EN, Grauer GF, Greco DS, et al. Comparison of the effects of diltiazem and aspirin on platelet aggregation in cats. J Am Anim Hosp Assoc 1996;32:11-18.
21. Hogan DF, Andrews DA, Talbott KK, et al. Evaluation of antiplatelet effects of ticlopidine in the cat. Am J Vet Res 2004;65:327-332.
22. Parise P, Hauert J, Iorio A, et al. Streptokinase and rt-PA activate platelets by a different way: implications on the rethrombosis rate after their administration in myocardial infarction. J Lab Clin Med 1995;125:212-221.
23. Fitzgerald DJ, Catella F, Roy L, et al. Marked platelet activation in vivo after intravenous streptokinase in patients with acute myocardial infarction. Circulation 1988;77:142-150.
24. Collet JP, Montalescot G, Lesty C, et al. Disaggregation of in vitro preformed platelet-rich clots by abciximab increases fibrin exposure and promotes fibrinolysis. Arterioscler Thromb Vasc Biol 2001; 21:142-148.
25. 2 antagonist, on streptokinase-induced thrombolysis in the rabbit. Thromb Haemost 1993; 69:268-271.
26. Bednar MM, Quilley J, Russell SR, et al. The effect of oral antiplatelet agents on tissue plasminogen activator-mediated thrombolysis in a rabbit model of thromboembolic stroke. Neurosurgery 1996; 39:352-359.
27. 1 accelerates thrombolysis by tissue plasminogen activator. Blood 1989;73:1213-1217.
28. Willerson JT, Golino P, McNatt J, et al. Role of antiplatelet agents as adjunctive therapies in thrombolysis. Am J Cardiol 1991;67:12A-18A.
29. Yashuda T, Gold HK, Yaoita H, et al. Comparative effects of aspirin, a synthetic thrombin inhibitor and a monoclonal antiplatelet glycoprotein IIb/IIIa antibody on coronary artery reperfusion, reocclusion and bleeding with recombinant tissue-type plasminogen activator in a canine preparation. J Am Coll Cardiol 1990;16:714-722.
30. 2-receptor antagonists markedly enhances thrombolysis and prevents or delays reocclusion after tissue-type plasminogen activator in a canine model of coronary thrombosis. Circulation 1989;79:911-919.
31. Second International Study of Infarct Survival (ISIS-2). Collaborative study group randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17,787 cases of suspected acute myocardial infarction: ISIS-2. Lancet 1988;2:349-360.
32. Yao SK, Ober JC, Ferguson JJ, et al. Clopidogrel is more effective than aspirin as adjuvant treatment to prevent reocclusion after thrombolysis. Am J Physiol 1994;267:H488-H493.
33. Taka T, Okano E, Seki J, et al. Effects of clopidogrel on platelet activation and coagulation of non-anticoagulated rat blood under high shear stress. Haemostasis 1999;29:189-196.
34. Fareed J, Messmore HL. Clopidogrel. Semin Thromb Hemost 1999;25:1-84.
35. Yang LH, Hoppensteadt D, Fareed J. Modulation of vasoconstriction by clopidogrel and ticlopidine. Thromb Res 1998;92:83-89.
36. Herbert JM, Defreyn TG, Maffrand JP. Inhibitory effect of clopidogrel on platelet adhesion and intimal proliferation after arterial injury in rabbits. Arterioscler Thromb 1993;13:1171-1179.
37. CAPRIE Steering Committee. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet 1996;348:1329-1339.
38. Yusuf S, Zhao F, Mehta SR, et al. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 2001;345:494-502.
39. Pereillo J-M, Maftouh M, Andrieu A, et al. Structure and stereochemistry of the active metabolite of clopidogrel. Drug Metab Dispos 2002;30:1288-1295.
40. Colucci M, D'Aprile AM, Italia A, et al. Thrombin activatable fibrinolysis inhibitor (TAFI) does not inhibit in vitro thrombolysis by pharmacological concentrations of t-PA. Thromb Haemost 2001; 85:661-666.
41. Antiplatelet Trialists' Collaboration. Secondary prevention of vascular disease by prolonged antiplatelet treatment. Br Med J Clin Res Educ 1988;296:320-331.
42. Rahimtoola SH, Enriquez-Sarano M, Schaff HV, et al. Mitral valve disease. In: Fuster V, Alexander RW, O'Rourke RA, eds. Hurst's the heart. 10th ed. New York: McGraw-Hill Book Co, 2001;1697-1719.
43. Alexander RW, Pratt CM, Ryan TJ, et al. Diagnosis and management of patients with acute myocardial infarction. In: Fuster V, Alexander RW, O'Rourke RA, eds. Hurst's the heart. 10th ed. New York: McGraw-Hill Book Co, 2001;1275-1342.
44. Vinters HV, Jahan R. Interactions between heart and brain. In: Silver MD, Gotlieb Al, Schoen FJ, eds. Cardiovascular pathology. 3rd ed. Philadelphia: Churchill Livingstone, 2001;471-492.
45. Charles RG, Epstein EJ, Holt. S, et al. Coronary embolism in valvular heart disease. Q J Med 1982;51;147-161.
46. Maddoux GL, Goss JE, Ramo BW, et al. Left main coronary artery embolism: a case report. Cathet Cardiovasc Diagn 1987; 13:394-397.
47. Simoes MV, Felix PR, Marin-Neto JA. Acute myocardial infarction complicating the clinical course of dilated cardiomyopathy in childhood. Chest 1992;101:271-272.
48. Gersh BJ, Opie LH. Antithrombotic agents: platelet inhibitors, anticoagulants, and fibrinolytics. In: Opie LH, ed. Drugs for the heart. 4th ed. Philadelphia: WB Saunders Co, 1989;1097-1131.
49. Swedish Angina Pectoris Aspirin Trial Group. Double-blind trial of aspirin in primary prevention of myocardial infarction in patients with stable chronic angina pectoris. Lancet 1992;340:1421-1425.
50. Dutch Transient Ischemic Attack Trial Study Group. A comparison of two doses of aspirin (30 mg vs. 283 mg a day) in patients after a transient ischernic attack of minor ischemic stroke. N Engl J Med 1991;325:1261-1266.
51. Swedish Aspirin Low-dose Trial Collaborative Group. Swedish Aspirin Low-dose Trial (SALT) of 75 mg aspirin as secondary prophylaxis after cerebrovascular ischaemic events. Lancet 1991; 338:1345-1349.
52. Fuster V, Dyken ML, Vokonas PS, et al. Aspirin as a therapeutic agent in cardiovascular disease. Circulation 1993;87:659-675.
53. Erickson LA, Ginsberg MH, Loskutoff DJ. Detection and partial characterization of an inhibitor of plasminogen activator in human platelets. J Clin Invest 1984;74:1465-1472.
54. Yang LH, Hoppensteadt D, Fareed J. Modulation of vasoconstriction by clopidogrel and ticlopidine. Thromb Res 1998;92:83-89.
55. Umemura K, Ishihara H, Nakashima M. Anti-platelet effects of clopidogrel in rat middle cerebral artery thrombosis model. Thromb Res 1995;80:209-216.
56. Dupin JP, Gryglewski RJ, Gravier D, et al. Synthesis and thrombolytic activity of new thienopyrimidinone derivatives. J Physiol Pharmacol 2002;53:625-634.
57. Gryglewski RJ, Dupin JP, Uracz W, et al. Thrombolysis by thienopyridines and their congeners. J Physiol Pharmacol 2000; 51:683-693.
58. Gryglewski RJ, Korbut R, Swies J, et al. Thrombolytic action of ticlopidine: possible mechanisms. Eur J Pharmacol 1996; 308:61-67.